Krsnaa Diagnostics Reports Strong Q1 FY26 Results, Recommends ₹2.75 Final Dividend
The positive financial results and dividend recommendation are favorable for investors, suggesting operational strength. However, the significant income tax demand, even if contested by management, introduces a notable element of uncertainty that tempers the overall positive impact.
The company reported strong year-on-year growth in both standalone and consolidated revenue and profit, indicating good financial performance. The recommendation of a final dividend further adds to the positive sentiment, despite the ongoing income tax appeal.
* Krsnaa Diagnostics Limited's Board of Directors, at their meeting on August 11, 2025, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. * For the quarter ended June 30, 2025, the company reported consolidated revenue from operations of ₹ 192.98 crore, a significant increase from ₹ 170.23 crore in the same quarter of the previous fiscal year. * Consolidated profit for the quarter rose to ₹ 20.52 crore, up from ₹ 17.92 crore year-on-year. Basic consolidated earnings per share (EPS) stood at ₹ 6.35, compared to ₹ 5.55 in the prior year. * Standalone revenue from operations for the quarter was ₹ 175.61 crore, an increase from ₹ 163.16 crore year-on-year. Standalone profit for the quarter grew to ₹ 19.56 crore from ₹ 18.18 crore, with basic standalone EPS at ₹ 6.10, up from ₹ 5.63. * The Board recommended a final dividend of ₹ 2.75 per equity share for the financial year 2024-25. The record date for the final dividend payment is Friday, September 12, 2025. * The 15th Annual General Meeting (AGM) will be held on Thursday, September 25, 2025, through Video Conferencing/Other Audio Visual Means. * The company disclosed that it received assessment orders from Income Tax authorities for Assessment Years 2017-18, 2020-21, 2021-22, 2022-23, and 2023-24, resulting in a total demand of ₹ 51.39 crore due to additions for undisclosed income and disallowance of deductions. * The company has filed an appeal against these orders. It has paid ₹ 3.93 crore under protest for AY 2022-23 and requested to adjust ₹ 6.35 crore from tax refunds for AY 2024-25 against other amounts to be paid under protest. * The management believes these demand orders are not tenable and will not have a material impact on the company's financial position or performance.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.